This study provides insights into the disparate mechanisms of antitumor immunity and effects on tumor-associated blood vessels, comparing anti-VEGF and anti-VEGFR targeting in extracranial and metastatic melanoma models, including in BrMs, which has not been reported. This evidence concerns the gene VEGFA and neoplasm.